Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · Mutual

AlphaCentric Life Sciences and Healthcare Fund AlphaCentric Life Sciences and Healthcare Fund Class A (LYFAX)

Ticker LYFAX · Since 2019-11-29 · · Holdings as of Jun 30, 2026

Expense ratio
1.66%$166/yr per $10k
5-yr return
+4.1%annualized
1-yr return
+20.6%as of Dec 2025
Net assets
$46.6Mall share classes
Holdings
62

Bottom line

Is LYFAX a good fund? The bottom line

LYFAX is a share class of AlphaCentric Life Sciences and Healthcare Fund, an actively managed health care sector mutual fund from Mutual.

Annual fees run 1.66% — about $166 a year on every $10,000 invested, more expensive than 86% of health care sector funds we track.

It returned +20.6% over one year, +4.1% a year over five years (as of Dec 31, 2025, per its prospectus).

With $46.6 million in net assets and 62 holdings, its largest position is Gilead Sciences Inc (5.5%) and the top 10 make up 40.7% of the portfolio.

This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.

What to watch

  • Expensive for its category (1.66%)
  • Front-end sales load up to 5.75%
  • 12b-1 marketing fee of 0.25% a year
  • Small fund ($46.6 million) — small funds are likelier to close
  • High turnover (107% a year) can mean more taxable distributions

Updated Nov 19, 2026

What LYFAX invests in

The Fund?s investment objective is long-term capital appreciation.

The Fund seeks to achieve its investment objective by investing in the life sciences and healthcare related companies that the Fund?s investment sub-advisor, Kennedy Capital Management LLC (the ?Sub-Advisor?), believes have the potential to appreciate in value. Under normal market conditions, the Fund invests at least 80% of its net assets (plus borrowings for investment purposes) in the securities of companies in the life sciences and healthcare sectors , which the Fund defines to be the category of companies related to producing or supplying facilities, supplies, technology, pharmaceuticals, equipment, devices or services for the preservation and care of a person?s or animal?s health . The Fund invests in equity securities, primarily common stock, of these companies and may also invest, from time to time, in exchange traded funds (?ETFs?) that primarily invest in these companies. The…

From the fund's prospectus (filed Jul 28, 2026).

LYFAX performance

Fund calendar-year total returns, 2020–2025 2020: +54.4%; 2021: −3.6%; 2022: −1.1%; 2023: +6.9%; 2024: −0.4%; 2025: +27.9% +54.4% 2020 −3.6% 2021 −1.1% 2022 +6.9% 2023 −0.4% 2024 +27.9% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
LYFAX+20.6%+4.1%—
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full LYFAX performance history →

What LYFAX costs

On a $10,000 investment, LYFAX's 1.66% expense ratio costs about $166 a year. The prospectus estimates $3,039 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full LYFAX fee table →

LYFAX top 10 holdings

#Holding% of fund
1Gilead Sciences Inc5.53%
2Vertex Pharmaceuticals Inc5.33%
3Astrazeneca Plc4.63%
4First American Funds Inc4.26%
5Roivant Sciences Ltd3.67%
6Argenx Se3.59%
7Neurocrine Biosciences Inc3.51%
8Incyte Corp3.51%
9Axsome Therapeutics Inc3.43%
10Apogee Therapeutics Inc3.28%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 40.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to LYFAX

More funds like LYFAX →

LYFAX FAQ

What is the expense ratio of LYFAX?
LYFAX's expense ratio is 1.66%, which works out to about $166 a year for every $10,000 invested. The prospectus estimates total costs of $3,039 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is LYFAX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.66%); front-end sales load up to 5.75%; 12b-1 marketing fee of 0.25% a year; small fund ($46.6 million) — small funds are likelier to close; high turnover (107% a year) can mean more taxable distributions. This is general information, not personalized advice.
What does LYFAX hold?
LYFAX's largest holdings are Gilead Sciences Inc (5.5%), Vertex Pharmaceuticals Inc (5.3%), Astrazeneca Plc (4.6%), First American Funds Inc (4.3%), Roivant Sciences Ltd (3.7%). It holds 62 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is LYFAX's 5-year return?
LYFAX returned +4.1% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
Does LYFAX have a sales load?
Yes. LYFAX has a maximum front-end sales charge of 5.75%. It may charge a deferred sales charge of up to 1% if sold early.
Who manages LYFAX?
LYFAX is offered by Mutual through Mutual Fund Series Trust.